Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
Together, they discuss Rosana and Marty's recent publication regarding a virus-like element in our genome known as LINE-1. LINE-1, part of our "dark genome," was ignored as junk DNA for years, but is increasingly recognized to contribute to the pathology of autoimmunity, cancer, neurodegeneration, and aging. Rosana and Marty discuss how the discovery was made as well as how Rome Therapeutics is developing a platform to target LINE-1 and other factors that are part of the "dark genome" for the treatment of disease.
Additional reading:
Carolyn Bertozzi and Degrading Drugs for Problematic Proteins
Deploying AI Platforms to Identify Sepsis
Discovery, Translation, and the State of Bio Today
Engineering an Epigenome Editor
Evolving Embodied Intelligence
Building Digital Health's Github
The Genetic Testing (R)Evolution
The Problem with Urgent Care
Viral Genomes from A to Z
World’s largest supercomputer v. biology’s toughest problems
The Trials of Clinical Trials
The New Science of Cell Shape
Journal Club: Sleeping Under the Star-Shaped Cells
The Power of Patient-Centric Healthcare
Journal Club: Hunting the Eagle Killer
Journal Club: Sourcing the Secrets of Climate Adaptation
Evolution: Animals, Aliens, and Ourselves
Journal Club: Bioengineering Birth... Again!
Solving Medical Mysteries in the World of Rare Disease
Journal Club: Taming the Taste for Blood
Create your
podcast in
minutes
It is Free